POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
34 hedge funds and large institutions have $248M invested in POINT Biopharma Global Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
62% more funds holding
Funds holding: 21 → 34 (+13)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
25% more capital invested
Capital invested by funds: $198M → $248M (+$50M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$70.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$9.12M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.53M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.47M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.35M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1M |
| 5 |
D.E. Shaw & Co
New York
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPIG
26
Chicago Partners Investment Group
Chicago,
Illinois
| $92K | +$93.9K | +10,295 | New |
|
27
Victory Capital Management
San Antonio,
Texas
| $81K | +$96.2K | +10,544 | New |
|
|
PHK
28
Point72 Hong Kong
Hong Kong
| $63K | +$75.2K | +8,241 | New |
|
29
Wells Fargo
San Francisco,
California
| $57K | +$67.9K | +7,447 | New |
|
30
Bank of America
Charlotte,
North Carolina
| $43K | +$51.2K | +5,615 | New |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $30K | +$35.2K | +3,861 | New |
|
|
CSS
32
Cubist Systematic Strategies
Stamford,
Connecticut
| $28K | +$33.2K | +3,637 | New |
|
33
Morgan Stanley
New York
| $27K | +$31.8K | +3,485 | New |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $23K | +$27.4K | +3,000 | New |
|
|
35
Wellington Management Group
Boston,
Massachusetts
| – | -$3.53M | -343,410 | Closed |
|
|
MF
36
Magnetar Financial
Evanston,
Illinois
| – | -$159 | -15,514 | Closed |
|
37
UBS Group
Zurich,
Switzerland
| – | -$5K | -509 | Closed |
|
PNT Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2021, worth a combined $248M — up 25% from $198M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PNT positions and 3 closed out — a net gain of 15 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was RA Capital Management, adding an estimated $70.8M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.53M sold.
- 34 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $248M of POINT Biopharma Global Inc. Common Stock stock for Q3 2021, up 25% quarter-over-quarter.
- 18 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +15 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2021 was RA Capital Management, an estimated $70.8M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $3.53M sold.
Based on aggregated 13F filings for Q3 2021.